Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid HIV-1 genotyping assay for the detection of capsid mutations.

Journal of medical virology - 1 Dec 2023

Margot Nicolas, Naik Vidula, Nekkalapudi Anurag, Boopathy Archana, Falkard Brie, Callebaut Christian

Abstract excerpt

Human immunodeficiency virus (HIV) capsid is one of the most recent viral proteins successfully targeted for the development of antiretrovirals. Lenacapavir is a first in class HIV-1 capsid inhibitor that was recently approved for the treatment of highly treatment-experienced people with HIV in combination with other anti-HIV drugs. Owing to the novelty of the viral target, methods to characterize the potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Capsid
Share to Capsid Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to HIV Infections

Share to Mutation

Source

Identifiers

PMID: 38063404
DOI: 10.1002/jmv.29292

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid HIV-1 genotyping assay for the detection of capsid mutations.PMID 38063404Read ↗

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.Semantic proximity Read ↗

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavirSemantic proximity Read ↗

HIV-1 capsid variability: viral exploitation and evasion of capsid-binding moleculesSemantic proximity Read ↗

HIV-1 gag genotypic resistance testing using short-read and long-read next-generation sequencing technologies.Semantic proximity Read ↗

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.Semantic proximity Read ↗

Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing RegimenSemantic proximity Read ↗

HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor LenacapavirSemantic proximity Read ↗

Inhibitors of the HIV-1 capsid, a target of opportunitySemantic proximity Read ↗

Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patientsSemantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

HIV Capsid is a Tractable Target for Small Molecule Therapeutic InterventionSemantic proximity Read ↗

Lenacapavir binding to immature Gag triggers the emergence of giant HIV-1 virionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.